Evidence map›Paper›PMID 36311710›Full record

ArticleFrontiers in immunology2022

Editorial: New biomarkers for the diagnosis and treatment of systemic lupus erythematosus.

Andras Perl, Nancy Agmon-Levin, José C Crispín, Trine N Jorgensen

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andras PerlDepartment of Medicine, College of Medicine, State University of New York, Upstate Medical University, Syracuse, NY, United States.
Nancy Agmon-LevinThe Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel.
José C CrispínDepartment of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Trine N JorgensenDepartment of Inflammation & Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States.

Funding

SLE Treatment with N-acetylcysteineU01AR076092 · NIAMS · UPSTATE MEDICAL UNIVERSITY · PI Michael P McDermott, Andras Perl · 2020 to 2026
$7.9M
Metabolic Control of T-cell Lineage Specification in SLER01AI072648 · NIAID · UPSTATE MEDICAL UNIVERSITY · PI PERL, ANDRAS · 2008 to 2024
$6.1M
IMPACT OF HRES-1 ENDOGENOUS RETROVIRUS IN SLER01AI048079 · NIAID · UPSTATE MEDICAL UNIVERSITY · PI PERL, ANDRAS · 2000 to 2013
$2.7M
Endocytic Control of Autophagosome Formation in Lupus T cellsR01AI122176 · NIAID · UPSTATE MEDICAL UNIVERSITY · PI PERL, ANDRAS · 2016 to 2020
$2.0M
Effector functions and cellular targets of pathogenic plasmacytoid cells in lupus.R01AI118774 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI JORGENSEN, TRINE NORGAARD · 2017 to 2021
$2.0M
Treatment of SLE with N-acetylcysteineR01AT004332 · NCCIH · UPSTATE MEDICAL UNIVERSITY · PI PERL, ANDRAS · 2008 to 2011
$1.6M
Treatment of SLE with sirolimusR34AI141304 · NIAID · UPSTATE MEDICAL UNIVERSITY · PI PERL, ANDRAS · 2019 to 2019
$243k
NCCIH NIH HHS R01 AT004332NIAID NIH HHS R01 AI048079NIAID NIH HHS R01 AI072648NIAID NIH HHS R01 AI118774NIAID NIH HHS R01 AI122176NIAID NIH HHS R34 AI141304NIAMS NIH HHS U01 AR076092
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lupus Erythematosus, SystemicLupus NephritisBiomarkersHumansBiomarkersbiomarkerlupus (SLE)machine learningmulti-omics analysessystems biology

Identifiers

PMID36311710
PMCPMC9599399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.